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Summary
Congenital chloride diarrhea (CLD) is an inherited in-
testinal disorder caused by mutations in the down-reg-
ulated in adenoma gene. In Finland, the disease is prev-
alent because of a founder effect, and all but one of the
CLD-associated chromosomes carry the same mutation,
V317del. In Poland, another area with a high incidence
of CLD, as many as seven different mutations have been
detected so far. A third known cluster of CLD, around
the Persian Gulf, has not been genetically studied. We
studied the allelic diversity of CLD in Poland, in Saudi
Arabia and Kuwait, and in three isolated families from
North America and Hong Kong. Altogether, eight novel
mutations were identified, making a total of 19 known
CLD gene mutations. The Polish major mutation
I675–676ins was found in 47% of the Polish CLD-as-
sociated chromosomes. Haplotype analysis and cluster-
ing of the I675–676ins mutation supported a founder
effect and common ancestral origin. As in Finland, a
major founder effect was observed in Arab patients:
94% of the CLD-associated chromosomes carried a non-
sense mutation, G187X, which occurred in either a con-
served ancestral haplotype or its derivative. Our data
confirm that the same locus is mutated in all cases of
CLD studied so far. In Poland, a relatively common
founder mutation is likely to highlight a set of rare mu-
tations that would very rarely produce homozygosity
alone. This suggests that mutations in the CLD locus
are not rare events. Although the disease is thought to
be rare, undiagnosed patients may not be uncommon.
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Introduction
Mutations in the down-regulated in adenoma gene
(DRA [MIM 126650]) recently have been shown to
cause congenital chloride diarrhea (CLD [MIM
214700]; McKusick 1994), an intestinal disorder of
chloride and bicarbonate transport (Ho¨glund et al.
1996). The DRA gene initially was cloned on the basis
of its absent expression in colonic neoplasia (Schweinfest
et al. 1993). Since then, its involvement in intestinal
sulfate, oxalate, (Silberg et al. 1995) and chloride trans-
port has been demonstrated (R. H. Moseley, P. Ho¨glund,
D. G. Silberg, S. Haila, C. Holmberg, A. de la Chapelle,
G. D. Wu, and J. Kere, unpublished data). The predicted
CLD protein is a transmembrane protein that, by amino
acid homology, belongs to the sulfate permease gene
family. Despite the clinical observation of both chloride
and bicarbonate trafficking defects in CLD, this set of
transporters is distinct from the genes encoding known
human anion exchangers (AE1–AE3).
The clinical picture of CLD includes a life-long watery
diarrhea with a high concentration of chloride, electro-
lyte disturbances, and metabolic alkalosis (Darrow
1945; Gamble et al. 1945; Perheentupa et al. 1965; No-
rio et al. 1971; Holmberg et al. 1977). Patients receiving
adequate salt and fluid supplementation grow and de-
velop normally and may have a normal life span (Holm-
berg 1986). Complications such as renal impairment and
gout result from chronic dehydration and vascular con-
traction (Pasternack and Perheentupa 1966; Holmberg
et al. 1977; Holmberg 1986; Nuki et al. 1991) and are
prevented most effectively by supplementation therapy.
A few reported patients with a later-age diagnosis of
CLD probably have coped with their disease by the con-
sumption of salty foods (Pearson et al. 1973; Holmberg
et al. 1977; Leskinen 1996); their long-term renal prog-
nosis is unknown.
The disease is known worldwide but, in most popu-
lations, has been reported only occasionally. Three
regions with elevated incidence include Finland, Poland,
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and countries around the Persian Gulf. In Poland, there
are ∼40 known patients with CLD (Tomaszewski et al.
1987; J. Socha, unpublished data), and one or two new
patients emerge annually. No specific ethnic groups have
been recognized as having increased incidence. The di-
agnostics of childhood chronic diarrhea has been fo-
cused in one hospital (Center of Child Health, Warsaw),
whose clinicians are familiar with this disorder. Thus the
number of undiagnosed patients with CLD is probably
low in this country, and the disease incidence is ∼1:
200,000. Because of the dispersed health-care services
in Saudi Arabia and Kuwait, the incidence of CLD is
more difficult to estimate. So far, 46 patients have been
reported (Lubani et al. 1989; Shaltout et al. 1989; Ab-
dullah et al. 1990; Khan and Yaish 1992; Kagalwalla
1994; Al-Abbad et al. 1995). Since a significant number
of patients are likely to remain undiagnosed, incidence
figures as high as 1:5,500 have been estimated (Kagal-
walla 1994). Approximately one-fourth of all patients
worldwide occur in the Finnish population, where at
least 52 patients are currently known. In Finland, the
high incidence (1:10,000 in the high-risk area; Ho¨glund
et al. 1995) is caused by genetic drift in combination
with two successive founder effects, the latest of which
occurred during the 16th century (Norio et al. 1971;
Norio 1981; de la Chapelle 1993). Not surprisingly, a
single ancestral mutation, V317del, has been found in
all but one of the Finnish CLD chromosomes studied
(Ho¨glund et al. 1996, 1998).
In the present investigation, we studied the genetic
background of CLD in two other high-incidence areas:
(1) Poland and (2) Saudi Arabia and Kuwait. We con-
structed CLD-associated haplotypes spanning 800 kb of
genomic DNA around the CLD gene, searched for ad-
ditional mutations by SSCP and genomic sequencing,
and compared the spectrum of mutations versus the hap-
lotype data and genealogical information.
Subjects, Material, and Methods
Subjects and Samples
Altogether, 32 patients diagnosed as having CLD were
studied. The Polish patients were 11 males and 9 females
born during 1969–95. DNA samples were available
from these 20 patients and from 32 parents. The four
Saudi Arabian families consisted of five patients, three
unaffected siblings, and eight parents. The Kuwaiti fam-
ilies consisted of five patients and six parents. In addi-
tion, two isolated cases of CLD, one from Canada and
one from the United States, were studied, as was a family
with three affected members, from Hong Kong. The clin-
ical phenotype of all patients was characterized by a
profuse diarrhea with a high chloride content (190
mmol/liter) in watery stools, justifying the diagnosis of
CLD. There were no obvious phenotypic differences be-
tween these patients. The severity of the intestinal chlo-
ride transport defect cannot be predicted on the basis of
the absolute concentration of chloride in stools, since it
fluctuates, depending on diet, hydration status, salt in-
take, and electrolyte balance. To test the population fre-
quency of each sequence change observed, DNA samples
from Finnish blood donors were used as controls. DNA
was prepared from blood, as described elsewhere (Lahiri
and Nurnberg 1991). Appropriate informed consent was
obtained from each individual participating in the study.
Mutation Analyses
Mutations in the coding region of the CLD gene were
detected and identified as described elsewhere (Ho¨glund
et al. 1998). In brief, each exon of the CLD gene was
amplified by use of specific intronic primers (Haila et
al., in press). The amplified exons were screened, by
SSCP analysis, for a mobility change, and suggested se-
quence changes were identified by sequencing using dye-
terminator chemistry and an automated sequencer (ABI
373A; Applied Biosystems). The observed mutations
were screened in control individuals by either direct vi-
sualization of the altered PCR fragment size in
polyacrylamide gel (for mutations 268–269insAA,
I675–676ins, and 1609delA), SSCP (for mutations
G187X and IVS11-GrA), or detection of either novel
restriction sites (for mutations IVS5-2ArG and L496R)
or loss of restriction sites present in wild-type alleles (for
mutation IVS5-1GrT).
Haplotype Analysis
DNA was amplified by use of four polymorphic mark-
ers—D7S2420, D7S496, D7S2459, and D7S2456 (Dib
et al. 1996)—as described elsewhere (Ho¨glund et al.
1995). These markers define a haplotype that, altogether,
spans 0.8 cM (0.8 Mb). The intermarker distances are
as follows: D7S2420–0 cM, 300 kb–D7S496–0 cM, 150
kb–D7S2459–0.8 cM, 350 kb–D7S2456. The PCR
products were separated by electrophoresis in 6% poly-
acrylamide gels, and the fragments were visualized by
silver staining. The CLD-associated haplotypes were
constructed manually. When parental samples were
available from one parent only (in the case of two Polish
families and four Kuwaiti families), haplotype identities
were inferred on the basis of the associated most con-
served haplotype.
Results
Analysis of the coding region and exon/intron bound-
aries of the CLD gene led to the identification of 8 novel
mutations, making the total number of all known mu-
tations 19 (fig. 1E and tables 1 and 2).
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Figure 1 Identification of five novel mutations of the CLD gene. The patients with CLD are denoted by blackened symbols (squares
denote males, circles denote females, and diamonds denote individuals whose gender is not known), and healthy control individuals and family
members are denoted by unblackened symbols (for those with no depicted mutation) or half-blackened symbols (for carriers). The 3-bp insertion
responsible for the Polish major mutation, I675–676ins, was identified, by PAGE, as an altered size of a genomic PCR fragment (A). The Saudi
Arabian and Kuwaiti major mutation, G187X, was screened for by SSCP analysis. The arrow indicates the reverse-strand homozygous CrA
sequence change leading to the mutation (B). The identification of two different nucleotide changes of the intron 5 acceptor site AG (IVS5-
1GrT and IVS5-2ArG) in two unrelated North American patients was accomplished by two separate restriction analyses. Both of the mutations
led to a loss of a restriction site for enzyme BsrI, and the ArG mutation generated an additional restriction site for MspI (C). An insertion
mutation (268–269insAA) in a Chinese family with three affected children is shown in a silver-stained polyacrylamide gel (D). The distribution
of all known CLD gene mutations is shown (E). Exons are denoted by numbered boxes (numbers have been omitted from short exons). The
thicker vertical bar in exon 2 marks the translation-initiation codon. Mutations are indicated are belonging to three classes: nonsense mutations
(NONS), caused by point mutations resulting in a stop codon (vertical bar), out-of-frame insertions (upward-pointing arrows), or deletions
(downward-pointing arrows); missense mutations (MISS), including amino acid substitutions (vertical bars), single-amino-acid insertions(upward-
pointing arrrow), or deletions (downward-pointing arrows); and splice-site mutations (SPLC), all in acceptor sites of the corresponding introns.
Poland
The most prevalent Polish mutation was an insertion
of three nucleotides (ATC) between nucleotides 2025
and 2026, which resulted in an in-frame addition of an
isoleucine in the predicted intracellular C-terminus of
the CLD protein (I675–676ins; see fig. 1). This insertion
mutation was found in 47% of all Polish disease-asso-
ciated chromosomes. Another Polish mutation charac-
terized here was a GrA substitution in the splice-accep-
tor site AG at intron 11, leading to the loss of the splice
site (IVS11-1GrA).
In studying a set of 17 Polish families by using four
polymorphic markers spanning 400 kb on both sides of
the CLD gene, we found 16 different CLD-associated
haplotypes (fig. 2A). An identical core haplotype could
be assumed in four sets of haplotypes with a unique
mutation each, supporting the hypothesis that these mu-
tations have the same ancestral origin. Genealogical
studies showed no close consanguinity between the fam-
ilies. The distribution of the birthplaces of all known
Polish CLD grandparents (fig. 3A) shows clustering in
the middle and southern parts of the country. The pat-
tern of CLD parents (fig. 3B) is less informative, a result
that is understandable in light of recent migrations.
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Table 1
CLD Patients Ascertained in the Present Study
Origin and
No. of Patients Mutations
Hong Kong:
3 268–269insAA, L496R
Canada:
1 IVS5-2ArG, 1609delA
United States:
1 IVS5-1GrT, P131R
Kuwait:
4 G187X, G187X
1 G187X, unknown
Saudi Arabia:
4 G187X, G187X
Poland:
1 IVS11-1GrA, H124L
2 I675–676ins, H124L
1 I675–676ins, 344delT
1 I675–676ins, Y527del
1 I675–676ins, 1548–1551delAACC
1 I675–676ins, G120S
2 I675–676ins, unknown
4 I675–676ins, I675–676ins
2 Unknown, unknown
However, not a single case was observed in the northern
cities. If we take a closer look at the spectrum of mu-
tations in separate geographical regions, the four mu-
tations each found in more than one CLD chromosome
showed clustering. The major insertion mutation was
most prevalent in the southern part of the country,
whereas Y305X, H124L, and 344delT occurred in the
eastern, southeastern, and middle parts of Poland, re-
spectively (fig. 3). Of the 34 Polish CLD chromosomes,
5 carried a unique mutation and 4 an unidentified
mutation.
Saudi Arabia and Kuwait
The most frequent Saudi Arabian and Kuwaiti mu-
tation was a GrT transversion at nucleotide position
559. The predicted amino acid change was a substitution
of glycine by the termination codon at 187 (G187X; see
fig. 1). The haplotypes segregating with G187X were
well conserved and suggested a common origin for this
mutation (fig. 2B). The geographical distribution of the
Saudi Arabian patients was throughout the country,
whereas the Kuwaiti patients reside within the Al-Jahra
region, which has X300,000 inhabitants (of whom
240,000 are Bedouins; data not shown).
North America and Hong Kong
So far, the most proximal mutation detected in this
gene is a 2-bp insertion (AA) between nucleotides 268
and 269. The insertion causes a frameshift leading to a
nonsense change at codon 91, followed by a termination
at codon 93 (fig. 1). The insertion mutation was present
in three affected sisters and their mother, from Hong
Kong, in heterozygous form. The second mutation seg-
regating in this family was a TrG transversion at nu-
cleotide position 1487, causing a leucinerarginine
amino acid substitution at codon 496. The three novel
North American mutations all were found in single dis-
ease-associated chromosomes only. The first one was a
deletion of nucleotide A at position 1609, leading both
to a frameshift and nonsense change at codon 537 and
to a termination codon at 575 in the predicted amino
acid sequence. The other mutation in this patient was
an ArG change at the AG acceptor site of intron 5,
leading to the loss of a splice site (IVS5-2ArG; see fig.
1). At the same splice-acceptor site, in another North
American patient, who elsewhere had been reported to
have a P131R mutation in her other CLD-associated
chromosome (Ho¨glund et al. 1998), there was a GrT
change (IVS5-1GrT; see fig. 1). The haplotypes of these
isolated patients were not studied.
Discussion
The detection of a set of 19 mutations in the CLD
gene in patients with CLD originating in several different
populations confirms that there is no locus heterogeneity
in CLD. Since the disease is believed to be rare world-
wide, the presence of clusters of CLD families residing
in certain geographic areas can, a priori, be considered
to be due to founder effects in these areas. In the case
of Finland, this hypothesis holds up well, since all but
one of the Finnish CLD patients are homozygous for the
same mutation, V317del (Ho¨glund et al. 1996, 1998),
that abolishes chloride-transport activity in vitro (R. H.
Moseley, P. Ho¨glund, D. G. Silberg, S. Haila, P. Holm-
berg, A. de la Chapelle, G. D. Wu, and J. Kere, unpub-
lished data).
In Saudi Arabia and Kuwait, a founder effect com-
bined with a high frequency of consanguineous mar-
riages, which increase locus homozygosity, are likely to
be responsible for the higher-than-average incidence of
CLD. In the Al-Jahra area, whence all our Kuwaiti pa-
tients originated, the overall rate of consanguineous
marriages is as high as 85%, and, of these, 95% are
paternal-first-cousin marriages. Parental consanguinity
was known in all Saudi Arabian and Kuwaiti CLD fam-
ilies included in this study.
The G187X mutation was found in all Saudi Arabian
and all but one of the Kuwaiti CLD-associated chro-
mosomes, and, in all cases, the 800-kb haplotype sur-
rounding the disease locus supported a common origin
of the mutation (fig. 2B). The Kuwaiti patients with
G187X in both chromosomes all carried a homozygous
800-kb haplotype (2-1-2-6 or 2-1-2-3), reflecting not
only close parental consanguinity (first-cousin mar-
Table 2
Summary of All Mutations Observed in the CLD Gene in CLD Patients
Population(s)
(No. of Patients) cDNA Change Exon Codon Predicted Coding Change Screening Method
Proportion
of Control
Chromosomes
North American (1) 177–178insCa 3 60 Frameshift leading to nonsense change at codon 60, fol-
lowed by stop at codon 70
Altered PCR-fragment size (PAGE) 0/80
Hong Kong (3) 268–269insAAb 3 90 Frameshift leading to nonsense change at codon 91, fol-
lowed by stop at codon 93
Altered PCR-fragment size (PAGE) 0/80
Polish (3) 344delTb,c 4 115 Frameshift leading to nonsense change at codon 115, fol-
lowed by stop at codon 133
Altered PCR-fragment size (PAGE) 0/336
Polish, Swedish (2) 358GrAa,b 4 120 Glycinerserine, G120S Gain of novel site for restriction enzyme
Eco57I
0/100
Polish (3) 371ArTb,c 4 124 Histidinerleucine, H124L Gain of novel site for restriction enzyme HinfI 0/316
North American (2) 392CrGa 5 131 Prolinerarginine, P131R Altered PCR-fragment mobility (SSCP) 0/104
Kuwaiti, Saudi
Arabian (9)
559GrTb 5 187 Glycinerstop, G187X Altered PCR-fragment mobility (SSCP) 0/130
North American (1) IVS5-1GrTb ) ) Change in the intron acceptor site AG at nt 1 of intron 5,
leading to loss of a splice site
Loss of a site for restriction enzyme BsrI 0/112
North American (1) IVS5-2ArGb ) ) Change in the intron acceptor site AG at nt 2 of intron 5
leading to the loss of a splice site
Gain of novel site for restriction enzyme BsrI,
loss for enzyme MspI
0/108
Polish (2) 915CrAa 8 305 Tyrosinerstop, Y305X Gain of novel site for restriction enzyme Bsu36I 0/82
Finnish (32) 951–953delGGTc 8 317 In-frame loss of a valine, V317del Altered PCR-fragment size (PAGE) 3/872
Polish (1) IVS11-1GrAb ) ) Change in the intron acceptor site AG at nt 1 of intron
11 leading to the loss of a splice site
Altered PCR-fragment mobility (SSCP) after di-
gestion with RsaI
0/84
Hong Kong (3) 1487TrGb 13 496 Leucinerarginine, L496R Gain of novel site for restriction enzyme CviJI 0/156
Polish (1) 1516delCa 14 505 Frameshift leading to nonsense change at codon 505, fol-
lowed by stop at codon 534
Altered PCR-fragment size (PAGE) 0/124
Polish (1) 1548–1551delAACCa 14 516 Frameshift leading to nonsense change at codon 518, fol-
lowed by stop at codon 534
Altered PCR-fragment size (PAGE) 0/124
Polish (2) 1578–1580delTTAa 14 527 In-frame loss of a Tyrosine, Y527del Altered PCR-fragment size (PAGE) 0/124
North American (1) 1609delAb 15 537 Frameshift leading to nonsense change at codon 537, stop
at codon 575
Loss of site for restriction enzyme XmnI 0/142
Polish (12) 2025–2026insATCb 18 676 In-frame addition of an isoleucine, I675–676ins Altered PCR-fragment size (PAGE) 0/168
Finnish (1) 2116delAa 19 706 Frameshift leading to nonsense change at codon 706, stop
at codon 711
Altered PCR-fragment size (PAGE) 0/170
a Source: Ho¨glund et al. (1998).
b Source: present study.
c Source: Ho¨glund et al. (1996).
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Figure 2 CLD-associated 800-kb haplotypes across the CLD gene region, in (A) a set of 17 unrelated Polish CLD families and (B) in
four Saudi Arabian and five Kuwaiti families. The associated mutations and their parental origin are denoted by blackened circles (maternal)
and blackened squares (paternal). The most likely localization of the CLD gene is indicated by the downward-pointing arrows.
riages) but, also, close interfamilial connections. In the
Saudi Arabian families, in which the degree of parental
consanguinity could not be specified, only one of the
patients carried a fully homozygous 800-kb haplotype,
and, as well, the overall spectrum of the haplotypes was
wider than that in the Kuwaitis.
Further evidence for the common origin of the major
G187X mutation in Kuwait and Saudi Arabia was pro-
vided by the population-historical data. Both the Saudi
Arabian population and the majority of the Kuwaiti
population descend from common ancestors, the Arabic
Bedouins who reside in the Persian Gulf desert areas.
Not only geographically but, also, historically and cul-
turally, Kuwait belongs to the Arabian Peninsula, with
a high rate of recent and present marriages between the
Kuwaiti and Saudi Arabian families. The accurate esti-
mation of the age or origin of the Arabic major mutation
is complicated both by migration and by the high rate
of consanguinity. It can be speculated that the mutation
might be younger than some of the most prevalent Eur-
opean CLD mutations (e.g., I675–676ins), since the
common ancestral haplotype is, in general, relatively
well conserved, especially among the Kuwaitis.
In Poland, the situation is more complicated, in that
the finding of many different mutations in a disease that
is considered very rare was unexpected. To understand
this phenomenon, we have haplotyped CLD chromo-
somes and have investigated the geographical distribu-
tion of the mutations in Poland, to trace their origins.
The most common mutation, I675–676ins, was found
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Figure 3 Distribution of the birthplaces for all known grand-
parents (A) and parents (B) of the Polish CLD patients. The parents
carrying I675–676ins, the major insertion mutation, are denoted by
blackened circles, the H124L mutation by asterisks, the 344delT mu-
tation by diamonds, and the Y305X mutation by blackened squares.
The mutations present either in a single chromosomes only or in chro-
mosomes with unidentified an mutation are denoted by unblackened
circles. Since the carrier status of the grandparental chromosomes was
not studied, half of the symbols in A are not associated with CLD.
to be present in 16/34 (47%) of all CLD chromosomes
of Polish origin. The study of flanking markers deline-
ated a common ancestral haplotype, which supported a
single origin of this mutation. Of chromosomes carrying
the I675–676ins mutation, 75% (12/16) shared the same
800-kb haplotype, 5-1-2-6, whereas the remaining four
chromosomes with this mutation had haplotypes 5-1-4-
6, 5-1-2-5, 5-1-2-4, and 5-2-2-4, which are likely to be
derivatives of the single ancestral mutated chromosome.
The mutation is likely to be at least several hundred years
old, since recombinations and microsatellite mutations
have had time to introduce changes within the 800-kb
haplotype in four chromosomes. For comparison, of 48
Finnish CLD chromosomes carrying the major mutation,
V317del, with an “age” estimated to be 450 years, or
19 generations (Ho¨glund et al. 1996), as many as 42/
47 (89%) carry the identical 800-kb haplotype segre-
gating with the disease (data not shown).
As in Finland, the geographic distribution of the
I675–676ins mutation in Poland shows clustering, al-
though it is more diffuse than that in Finland (fig. 3A).
The tendency of the clustering to become weaker for
parental versus grandparental birthplaces (fig. 3B) sug-
gests that migration in Poland has been much more ac-
tive during the past few decades than, for example, that
in Finland, where distinct geographical clustering of
CLD cases is still evident (Norio et al. 1971; Ho¨glund
et al. 1995). Furthermore, contrary to the situation in
Finland, the presence of a set of other mutations in-
creases the number of patients who are compound het-
erozygous for the major mutation.
In Poland, one of the mutations (344delT; see fig. 2A)
segregated with a fully conserved 800-kb haplotype in
three chromosomes. In fact, the conservation of these
haplotypes was found to extend as far as 5.8 cM (data
not shown). This finding, together with the putative ge-
ographical clustering of this mutation (fig. 3), suggests
that this mutation is relatively recent. Two of the mu-
tations (Y305X and H124L; see fig. 2A), with identical
200-kb and 550-kb core haplotypes in three disease-
associated chromosomes, may be older mutations, be-
cause there has been enough time for at least one (in the
case of H124L) or two (in the case of Y305X) ancient
recombinations to occur in the ancestral mutation-car-
rying chromosomes. Thus, altogether, there are one ma-
jor and three more-local founder effects in the Polish
population that have made CLD a relatively common
disease. The rest of the mutations were found only in a
single chromosome each (fig. 2A).
In the absence of a predominant founder mutation,
private mutations occurring alone in the population
would result in a CLD incidence much lower than we
have observed. Since, altogether, 12/17 patients (71%)
were either homozygotes or compound heterozygotes for
the major, I675–676ins mutation, only five CLD cases
would have occurred if this founder mutation did not
occur in Poland. Approximately half (16/34) of the CLD
chromosomes studied carry the I675–676ins mutation.
If random mating is assumed, results from the appli-
cation of the Hardy-Weinberg equation suggest that the
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Figure 4 Effect of the major insertion mutation (I675–676ins)
in Poland. Mutation-carrier status (horizontal axis) has been correlated
with CLD incidence (vertical axis), to Hardy-Weinberg equilibrium.
A doubling of carrier frequency, due to a founder mutation (right-
pointing arrow), leads to a fourfold increase in CLD incidence.
effect of the I675–676ins mutation increases approxi-
mately fourfold the incidence of CLD in Poland (fig. 4),
increasing it from ∼1/800,000 births to 1/200,000
births.
Multiple mutations in a specific gene restricted to a
certain geographical area have been reported in homo-
geneous isolates, such as that in Re´union Island (Alla-
mand et al. 1995). The finding, in the calpain gene, of
multiple distinct mutations (at least seven) that are re-
sponsible for recessively inherited limb-girdle muscular
dystrophy type 2A has been proposed as being due to
either digenic inheritance (Allamand et al. 1995; Beck-
mann 1996) or a high mutation rate (Zlotogora et al.
1996). In the digenic model, the disease manifestations
are controlled by two unlinked genes whose mutations
are required if the disease phenotype is to arise. Inac-
tivation of one of these genes would have little or no
effect on the biological phenotype, but mutations in both
would result in the disease. The second gene should be
more frequently mutated in the Re´union Island isolate
than elsewhere (Allamand et al. 1995; Beckmann 1996).
The functional evidence that the Finnish V317del mu-
tation alone abolishes the chloride-transport activity of
the CLD protein (R. H. Moseley, P. Ho¨glund, D. G.
Silberg, S. Haila, P. Holmberg, A. de la Chapelle, G. D.
Wu and J. Kere, unpublished data) makes the digenic
model a relatively unattractive explanation of the situ-
ation in Poland. However, mutations in the CLD gene
may be more frequent than previously has been assumed.
The well-conserved disease-associated haplotypes seg-
regating with some of the Polish mutations, together
with the observation of multiple different mutations in
single disease-associated chromosomes, are compatible
with a relatively recent occurrence of several mutations
in the CLD gene. There is, of course, no evidence that
mutation rates in the Polish population are generally
higher than those in other populations. Moreover, there
is no known selective advantage conferred to the carriers
of the CLD mutations, which is in contrast to the sit-
uation with either cystic fibrosis (Chao et al. 1994) or
thalassemia. It follows that multiple different mutations
should occur in all populations.
The diagnosis of CLD in a newborn may be difficult
if the physician is not aware of this “rare” possibility.
Even in countries, such Saudi Arabia, that have a high
incidence of CLD, decentralized health-care services re-
sult in the failure to diagnose a significant number of
patients. This is mainly because gastrointestinal prob-
lems and, in particular, diarrheal illnesses are among the
most common causes of morbidity and mortality among
infants. Even though the diagnosis of CLD is seemingly
simple (by fecal-chloride measurement), watery diarrhea
can be confused with urine, and an infant may succumb
undiagnosed. Provided that an undiagnosed infant sur-
vives its first 6 mo, it is likely to adopt a compensatory
diet with salty food, which improves its prognosis. In
such cases, complications are likely to shorten the life
span. The oldest known living patients are ages 32 years,
in Finland; 28 years, in Poland; and 14 years, in Saudi
Arabia. Our study suggests that the mutation frequency
in the CLD locus is not low, so CLD patients may be
born in all populations, and some of the Polish CLD
mutations may occur also in neighboring countries,
where CLD may be a more significant clinical problem
than previously has been thought. The importance of an
early diagnosis of CLD is stressed by the fact that ac-
curate therapy allows these children to grow and develop
normally and, probably, also to avoid complications in
the long term.
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